A curry dish is being recalled as a labelling problem means it could be a risk to some consumers. The Food Standards Agency ...

GSK said Tuesday that it made a deal to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash. The acquisition is expected to close in the first quarter of 2026 with an ...

Shares in RAPT Therapeutics Inc (NASDAQ:RAPT) soared 63.6% on Tuesday after pharmaceutical major GSK plc (LSE:GSK) said it ...

US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults ...

Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's experimental food allergy ...

The growing scourge of food allergies drove U.K. heavyweight pharmaceutical GSK to announce a $2.2 billion deal on Tuesday.

GSK has agreed to buy a pharmaceutical firm that is developing treatment for people with food allergies in a deal valued at 2 ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

GSK has reached an agreement to acquire Rapt Therapeutics, a US-based biotech developing therapies for treating people with ...

While there is skepticism regarding the science behind the new guidelines, schools are more concerned about any ...